Neurocognitive or neuro-ophthalmological conditions
Conditions
Interventions
Group A (Disease Group): 200 subjects with known or newly screened neurocognitive or neuro-ophthalmological conditions:N/A
Group B (Healthy Control Group): 200 subjects with sex and age matched with the recruited subjects from the disease group:N/A
Sponsors
Department of Ophthalmology and Visual Sciences (DOVS), The Chinese University of Hong Kong
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Participants who are willing to provide informed digital e-consent to participate in the study; 2. Completion of the study procedures and questionnaires; 3. Patients clinically diagnosed with neurocognitive, or neuro-ophthalmological conditions referred from physicians or self-volunteered; 4. Participants between the ages of 18 - 100; 5. Participants will be invited to join the study via open recruitment.
Exclusion criteria
Exclusion criteria: 1. Subjects receiving active treatment with N-methyl-D-aspartate (NMDA) receptor antagonists (e.g., memantine), Acetylcholinesterase (AChE) inhibitors (e.g. Donepezil, galantamine and rivastigmine) or psychiatric agent(e.g., antidepressant, antipsychotic); 2. Subjects with claustrophobia; 3. Subjects with a history of epilepsy or stroke within 24 months prior to the study participation; 4. Subjects with a history of seizure within the past 48 hours; 5. Subjects with severe behavioural and psychological symptoms of dementia (BPSD); 6. Subjects diagnosed with migraine headache; 7. Subjects who have an active implantable medical device, including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and/or sacral nerve stimulator; 8. Subjects that have profound hearing impairment; 9. Subjects with a history of brain or eye-related trauma (including surgeries); 10. Subjects that have consumed alcohol, coffee or any caffeine-containing substances within the past 12 hours; 11. Subjects with allergy to the materials of the display headset in contact with skin (e.g. nose pad, foam facial interface); 12. Failure to provide informed digital consent or to complete any part of the study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The diagnostic ability, repeatability and reproducibility on neurocognitive or neuro-ophthalmological conditions. ;The assessment on neurocognitive or neuro-ophthalmological conditions.; | — |
Secondary
| Measure | Time frame |
|---|---|
| The tolerability, safety and cost of VR assessment on patients diagnosed with neurocognitive or neuro-ophthalmological conditions.; | — |
Countries
China
Contacts
Public ContactCHONG Kam Lung Kelvin
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Outcome results
None listed